Science) utilizing most appropriate human resources  (Best Talent) to engage in dynamic research activities in  optimal environments (Best Place). In October 2013, we created Astellas Innovation  Management (AIM) to expand our use of external cutting- edge science. Previously, multiple divisions separately  explored external innovation opportunities of the preclini- cal stage. These functions have been integrated into AIM.  AIM is working closely with each research unit to system- atically secure innovation opportunities of a broad range  from bio-ventures and academia. Under the new research framework, we aim to capture  more opportunities for new drug discovery, by allocating  resources more flexibly, while still valuing the strategy of  selection and concentration we have pursued to date. In  addition to our focus therapeutic areas, we plan to allocate  Centered on the innovative new drug business, we have  begun looking at ways of delivering new value to patients  besides targeting new therapeutic areas. We make col- laborative efforts across varied fields such as surgery  and preventive care. We have established a special unit  inside Astellas and are implementing specific measures to  develop new business opportunities in fields outside of  therapeutic agents, leveraging the strengths we have built  up in our innovative pharmaceutical business. resources to new disease areas and drug discovery   platform technologies, while exploring potential uses of  external resources. As part of this approach, we con- cluded a number of alliances with bio-ventures and other  partners during fiscal 2013. We also established a special  unit dedicated to accelerating our initiatives in regenera- tive medicine and embarked on full-scale research into  cell therapies. Aiming to Provide New Value Developing New Therapeutic Areas and a Novel Technology Platform Business Strategy Best Science world’s cutting-edge  science Best place Engage research in an optimal  environment Best Talent utilize most  appropriate human  resources from within and outside of Astellas Research units Astellas innovation Management (AiM) Acquire opportunities to create innovation from bio-venture companies or academia coordination Continue to provide new solutions to patients  centered on the innovative drug business Innovative drug  business Medical devices (Combine with  drugs) Surgery (Answer to unmet needs) Others IT Preventative care Diagnosis Regenerative  medicine Approach to providing new value promoting Open innovation in Drug Discovery  Annual Report 2014 _  Astellas Pharma Inc.  27